Overview of Clinical Trial Study 1 (NCT03574597) was a multi-national, multi-center, placebo-controlled, double-blind trial to determine the effect of WEGOVY relative to placebo on major adverse cardiovascular events (MACE) when added to current standard of care, which included management of CV risk factors and individualized healthy lifestyle counseling (including diet and physical activity)
Remember that successful long-term weight management requires a comprehensive approach combining medication, nutrition, physical activity, and behavioural strategies, all tailored to your individual circumstances and health needs
The placebo group lost only 2.4 percent of their weight
(2.2) The usual recommended maintenance dosage of WEGOVY injection is 2.4 mg once weekly
Skeletal muscle, in particular, plays a pivotal role not only in mechanical functions such as movement and posture but also in whole-body protein metabolism and energy expenditure [86]
GLP-1 receptor agonists in heart failure: how far to expand use